Compare AERO & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AERO | IMCR |
|---|---|---|
| Founded | 1934 | 2008 |
| Country | Mexico | United Kingdom |
| Employees | 4084 | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | N/A | 2016 |
| Metric | AERO | IMCR |
|---|---|---|
| Price | $13.40 | $30.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $29.57 | ★ $61.82 |
| AVG Volume (30 Days) | ★ 637.9K | 351.7K |
| Earning Date | 03-02-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | $8.08 | $14.39 |
| Revenue Next Year | $5.01 | $8.19 |
| P/E Ratio | $7.95 | ★ N/A |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $12.85 | $23.15 |
| 52 Week High | $23.05 | $40.71 |
| Indicator | AERO | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 29.92 | 36.52 |
| Support Level | N/A | N/A |
| Resistance Level | $21.58 | $34.86 |
| Average True Range (ATR) | 1.11 | 1.44 |
| MACD | -0.34 | -0.24 |
| Stochastic Oscillator | 8.32 | 6.80 |
Grupo Aeromexico SAB de CV engages in providing air transport services for passengers, goods, and cargo, as well as loyalty program services, training and management services, franchise systems commercialization, and the management of investment in shares. Its services include passenger and cargo transportation, the Club Premier loyalty program, training, charter services, and other aviation-related activities. The company operates through a single operating segment, air transportation, and its geographical presence includes both domestic and international markets, with the majority of revenue coming from the international market.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.